On March 17, 2026, Incannex Healthcare Inc. (Nasdaq: IXHL) announced that it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This follows a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC, confirming that the company has cured its previous bid price deficiency. The company maintained a closing bid price of $1.00 per share or greater for eleven consecutive business days, from February 27 through March 13, 2026. This compliance reinstatement is significant as it ensures the company's continued listing on the Nasdaq Capital Market, alleviating a technical overhang that had previously affected its stock performance. Joel Latham, President and CEO of Incannex, expressed satisfaction with the company's financial position, highlighting approximately $75 million in cash and no debt. He emphasized the company's commitment to advancing its clinical programs, including IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder, both of which have shown promising clinical outcomes. The company aims to execute its clinical strategy effectively and unlock long-term value for its shareholders.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.